The main indications and application scope of baricitinib/alemin

Baricitinib (Baricitinib) is an oral small molecule JAK (Janus kinase) inhibitor jointly developed by Eli Lilly and Incyte. It is a targeted immunomodulatory prescription drug. Its core mechanism of action is to inhibit the immune-inflammatory response by inhibiting the JAK1 and JAK2 signaling pathways and blocking the excessive activation of various cytokines. This mechanism enables baricitinib to show broad application potential in a variety of autoimmune diseases and inflammation-related diseases.

Currently, the main indications for baricitinib focus on moderately to severely active rheumatoid arthritis (Rheumatoid Arthritis, RA). In such patients, it can effectively reduce joint inflammation, relieve pain, improve functional disability, and delay damage to joint structures on imaging. Baricitinib is suitable for patients who have an inadequate response to traditional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, and can be used alone or in combination with other DMARDs. The convenience of oral administration also allows for better patient compliance in long-term management.

In addition to rheumatoid arthritis, baricitinib is also approved internationally for the treatment of moderate to severe atopic dermatitis (Atopic Dermatitis). Atopic dermatitis is a chronic inflammatory skin disease with recurring course and severe itching. Baricitinib helps patients significantly relieve rash and itching by regulating the skin's immune response and the release of inflammatory factors. Clinical practice shows that the drug has good efficacy and tolerability in patients with refractory dermatitis.

In addition, baricitinib has received widespread attention for its immunomodulatory and anti-inflammatory effects in the treatment of new coronavirus pneumonia (COVID-19). The US FDA has approved its use for some hospitalized COVID-19 patients, especially moderate to severe cases with inflammatory storm or aerobic support. Studies have found that it improves respiratory function by reducing the immune system's overreaction and reducing the risk of inflammatory damage to the lungs.

Reference materials:https://go.drugbank.com/drugs/DB11817